Amongst them are histone methyltransferase and de-methylase inhibitors (see McGrath and Trojer 2015) and BET inhibitors (reviewed in Barbieri et al. 2013), a class of drugs that compete for binding of BET proteins (bromodomain and extra terminal family proteins) to acetylated histones and cause the downregulation of c-myc in myc-dependent cancers. Here, MYC is linked to cancer.